CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock News
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
CNTA Latest News, Press Relases and Analysis
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1...
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
The company tested a potential narcolepsy treatment in healthy, but sleep-deprived, volunteers.
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
Mentions: IFRX
Here's Why GE HealthCare Stock Sank in April
Hospital capital equipment spending in China continues to be sluggish. An improvement in the trade conflict will create upside potential for GE HealthCare, and management believes China is a long-term growth opportunity.
High-yield savings rates today: May 5, 2025 | APYs remain elevated despite a slight decline
High-yield savings accounts remain a strong option for savers…for now.
Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1...
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission...
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness...
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness...
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)